SLC5A2 and type 2 diabetes mellitus: Davies et al. concluded that DPP-4 inhibitors are more widely used than SGLT2 inhibitors or GLP-1 receptor agonists, despite the lack of evidence that DPP-4 inhibitors improve cardiorenal outcomes in patients with type 2 diabetes.